Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part, are able to follow the study requirements, and have signed a consent form agreeing to participate
- Women aged 18 to 75 years who are either postmenopausal, or pre- or perimenopausal (still having or recently stopping periods)
- People diagnosed with breast cancer that has come back or spread to other parts of the body, where laboratory testing has confirmed the cancer is positive for both ER (a hormone receptor) and HER2 (a specific protein)
- People who have at least one area of cancer outside the brain that can be measured using standard imaging guidelines (known as RECIST 1.1)
- People who have received no more than one previous treatment containing the drug trastuzumab for their recurrent or metastatic breast cancer
Who may not be able to join:
- People who have cancer that has spread to the brain or central nervous system and has not yet been treated
- People with bilateral breast cancer (cancer in both breasts at the same time), inflammatory breast cancer, or latent (hidden/occult) breast cancer
- People who have previously been treated with a CDK4/6 inhibitor drug (a type of targeted cancer therapy)
- People who are unable to swallow, have a blockage in the bowel, or have another condition that would affect how a tablet or capsule is absorbed by the body
- People who have had another type of cancer within the past 5 years or currently, with the exception of certain fully treated skin cancers (basal cell carcinoma) or cervical carcinoma in situ
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhanhong Chen, Master, Zhejiang Cancer Hospital
Phone: 17757194561
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.